The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | IPSOS: 1L atezolizumab vs single-agent chemotherapy in patients with platinum-ineligible NSCLC
Siow Ming Lee, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses results from a Phase II study of first-line (1L) atezolizumab vs single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) not eligible for a platinum-containing regimen. In the IPSOS trial (NCT03191786), 1L atezolizumab improved overall survival vs chemotherapy in platinum-ineligible patients with NSCLC, with twice as many patients estimated to be alive at 2 yr when treated with atezolizumab vs chemotherapy. No new or unexpected safety concerns were seen in this poor prognosis population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
